Nasdaq GlobeNewswire

Canadian Nuclear Laboratories : Canadian Nuclear Laboratories and TRIUMF to Host 11th Targeted-Alpha-Therapy Symposium

Del

Canada's national nuclear laboratory and leading particle accelerator centre partner to host global forum on targeted radiopharmaceutical therapy

CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and TRIUMF, one of the world's leading particle accelerator centres, jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 - 5, 2019 at the Fairmont Château Laurier in Ottawa.

TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.

In addition to a variety of industry and academic speakers and presentations, the TAT11 conference will feature an exhibition for companies to showcase their products and services, and will include a tour of the Chalk River Laboratories.

"Targeted-alpha-therapy is one of the most promising areas of nuclear medicine, and could represent a leap forward in radiation therapy," commented Kathy McCarthy, Lab Director, CNL. "Given CNL's history as a world-leader in the development and delivery of medical isotope technology, hosting this important international conference alongside TRIUMF, a leader in subatomic physics, was a natural fit. We look forward to welcoming participants from around the globe to discuss this exciting medical technology."

As part of Atomic Energy of Canada Limited's (AECL) Federal Nuclear S&T Work Plan, CNL is conducting research to evaluate alpha therapy delivery methods. This includes the construction of a small alpha radioisotope generator to provide isotopes for CNL and its collaborators. CNL is also taking the necessary steps to grow and expand its resources and capabilities to pursue related research projects, including work alongside TRIUMF.

"Canada has an existing and powerful particle accelerator infrastructure capable of enabling a greater supply of targeted-alpha-therapy isotopes," explains Paul Schaffer, TRIUMF Associate Lab Director - Life Sciences Division. "It's very fitting to be hosting the next conference here and I am looking forward to both learning from others and advocating for what Canada can contribute to this exciting field.

"TRIUMF has established the feasibility of producing important targeted-alpha-therapy isotopes such as Ac - 225 using its 500 MeV cyclotron; and is also in the process of upgrading its infrastructure to improve safety and reliability of large-scale, accelerator-based isotope production," explains Schaffer.

"Both CNL and TRIUMF are committed to improving the health of Canadians through nuclear medicine, and TAT11 is an important medium to foster international partnerships and collaborations that are necessary to advance this therapy," added Corey McDaniel, Vice-President, Business Development with CNL. "It is our hope that this forum will build awareness around alpha therapy and spur further research to accelerate the development of these isotopes."

For more information on TAT11, including a detailed conference itinerary and exhibitor information, please visit www.tat11.com.

About CNL

Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries. Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defense, security and life sciences, we provide solutions to keep these sectors competitive internationally.

With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced with a strong safety culture underscores every activity.

For more information on the complete range of Canadian Nuclear Laboratories services, please visit www.cnl.ca or contact communications@cnl.ca.

About TRIUMF

Established in 1968 in Vancouver, TRIUMF is Canada's particle accelerator centre. The lab is a hub for discovery and innovation inspired by a half-century of ingenuity in answering nature's most challenging questions. Powered by its complement of top talent and accelerator infrastructure - including the world's largest cyclotron - TRIUMF is driving the leading edges of advanced isotope science, innovation, and technologies to address fundamental and applied problems in particle and nuclear physics, and the materials and life sciences. In collaboration with 20 Canadian universities, TRIUMF's diverse community of nearly 600 multidisciplinary researchers, engineers, technicians, tradespeople, staff, and students create a unique incubator for Canadian excellence, as well as a portal to premier global collaborations. At TRIUMF, we drive more than scientific discovery -- our passion for understanding everything from the nature of the nucleus to the cosmos creates into inspiration, improved health, economic opportunity, and a better world for all.

For more information see http://www.triumf.ca. Connect on Twitter, Facebook, and Instagram: TRIUMFlab

Media Contacts:

Patrick Quinn
Director, Corporate Communications
CNL, 1-866-886-2325
communications@cnl.ca

Lisa Lambert
Head, Strategic Communications 
TRIUMF, 1-604-222-7356 
lisa@triumf.ca 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Canadian Nuclear Laboratories via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis22.5.2018 14:00Pressemelding

First Patient Begins Therapy with MABp1 for Treatment of Atopic Dermatitis AUSTIN, Texas, May 22, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating MABp1 in patients with moderate to severe Atopic Dermatitis (AD). The patient began treatment at Florida Academic Dermatology Center under the care of the Study's Chair, Dr. Francisco Kerdel. Dr. Kerdel commented, "Atopic dermatitis is a chronic inflammatory disease characterized by dry and scaly skin and severe, unrelenting itching. An inflammatory substance released by keratinocytes known as IL-1alpha, is believed to be a key trigger of inflammation in the disease. By neutralizing the activity of IL-1alpha, the new agent we are testing may arrest the disease process and offer relief from the debilitating symptoms. Today we treated a patient and I can report that within one hour of treatment, there was an unequiv

Apps Lead the Charge as Mobile Advertising Continues to Grow Worldwide22.5.2018 14:00Pressemelding

PubMatic's Q1 2018 QMI report highlights 84% YOY increase in mobile app monetized impression volumes globally REDWOOD CITY, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today released its first Quarterly Mobile Index (QMI) of 2018, which delved into key trends in mobile advertising for Q1. The report includes highlights around mobile app advertising growth, the continued expansion of header bidding adoption across mobile inventory, and the expansion of cross-channel monetization. There has been a significant shift in monetization opportunities for mobile app developers as in-app header bidding is introduced to the market. Already mainstream for mobile web inventory, as indicated in previous QMI reports, the introduction of header bidding technology for app inventory unlocked significant growth potential. Global app impression volumes monetized by PubMatic rose 84 percent year-over-year in Q1 2018, ou

Elite Capital & Co. Limited upgrades its quality management system to ISO 9001:201522.5.2018 12:00Pressemelding

LONDON, May 22, 2018 (GLOBE NEWSWIRE) -- The Public Relations Department of Elite Capital & Co. Limited has announced that it has upgraded its Quality Management System from ISO 9001:2008 to ISO 9001:2015, prompted by its keen desire to provide its customers with the best services and assert its steady strides in the global finance market under the leadership of a management team that stands on a solid ground. On this occasion Elite Capital's chairman, Kuwaiti businessman, Dr. Faisal Khazaal expressed his deepest thanks and congratulations to the Company's president, Mr. George Matharu and the members of the Board of Directors and all the members of the company's executive management for their exceptional efforts toward raising customer service to the highest levels. Elite Capital & Co. Limited is a private limited company that provides project-related services, including management, consultancy and funding, particularly for large infrastructure and commercial projects. Elite Capital &

Gunvor Group, Oceangold Tankers and Maas Capital Form ClearOcean Tankers JV22.5.2018 11:30Pressemelding

Gunvor SA / Gunvor Group, Oceangold Tankers and Maas Capital Form ClearOcean Tankers JV . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. "ClearOcean Tankers" has ordered 6 eco-friendly, scrubber-ready tankers NICOSIA, Cyprus, May 22, 2018 (GLOBE NEWSWIRE) -- Gunvor Group, one of the largest physical energy trading companies in the world, has entered into a joint venture with Oceangold Tankers and Maas Capital to form ClearOcean Tankers, a new ship holding company. The three partners hold an equal share in ClearOcean Tankers, which has been incorporated in Cyprus. ClearOcean Tankers has entered into shipbuilding contracts with STX Offshore & Shipbuilding Co. for four MR2 product tankers, and with Daehan Shipbuilding Co for two LR2 product tankers. All six of the contracted vessels will be delivered during the first half of 2019, and will be eco-friendly and scrubber-ready, in view of the International Marit

Doc re. GE Files Form 8-K22.5.2018 08:00Pressemelding

FAIRFIELD,Conn., May 22, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-K May 21, 2018 On May 21, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, p

Introducing AbacusNext International, Technology Solutions Provider to the UK, Europe, and Beyond22.5.2018 07:00Pressemelding

US Based AbacusNext incorporates AbacusNext International in Edinburgh, the new international headquarters of their globally expanding TaaS platform EDINBURGH, United Kingdom, May 22, 2018 (GLOBE NEWSWIRE) -- AbacusNext®, the largest Technology-as-a-Service (TaaS) provider for the professional services sector, today announced that two-time Queen's Award Winner HotDocs Ltd-recently integrated into the AbacusNext family of products-will be reorganized under the newly incorporated AbacusNext International Ltd. The HotDocs brand and product suite will remain as a subsidiary within AbacusNext International's expanded slate of products and services for business. From its new headquarters in Edinburgh, Scotland, AbacusNext International will bring the fully-managed private cloud solutions and business technology services they pioneered in the North American market to the UK and Europe for the first time. The centerpiece of AbacusNext International's TaaS platform is Abacus Private Cloud, offe

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom